Drug Profile
IONIS FGFR4Rx
Alternative Names: FGFRRx; IONIS-FGFR4Rx; ISIS 463588; ISIS-FGFR4Rx; ISIS-FGFRRxLatest Information Update: 12 Sep 2018
Price :
$50
*
At a glance
- Originator The University of Queensland
- Developer Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Obesity therapies
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 12 Sep 2018 Discontinued - Phase-II for Obesity in USA (SC)
- 01 Sep 2016 Ionis Pharmaceuticals completes the FGFR4-CS2 trial in Obesity in USA (SC) (NCT02476019)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals